Iksuda Therapeutics are featured in this month’s Nature magazine, a Q&A with their Chief… Continue Reading Iksuda Therapeutics – Forging stable relationships for antibody-drug conjugates.
Atelerix, pioneers in the storage and transport of cells at room temperature, announced today… Continue Reading Sanj Kumar joins Atelerix as Chief Business Officer
Invest Newcastle is attending the Smart City Expo World Congress to showcase our city… Continue Reading Newcastle delegation showcase our smart city to the world
Three of the Biosphere tenants have been shortlisted for the 2019 Bionow Awards. Iksuda Therapeutics,… Continue Reading Biosphere Tenants nominated for 2019 Bionow awards.
This Movember, the team at Iksuda are raising funds for men's health. We’ll be running,… Continue Reading Biosphere company do their bit for charity.
The Team at Newcastle Helix are celebrating after winning the ‘Collaborators Award’ in the EG… Continue Reading Newcastle Helix win prestigious real estate award
We talk to David Simpson, CEO at Iksuda Therapeutics about what they do, how… Continue Reading Q&A: Iksuda Therapeutics: Leading the way on helping to advance care for ovarian and lung cancer patients
Invest Newcastle recently attended BioJapan as part of a UK delegation led by MedCity… Continue Reading Taking Newcastle to the world at BioJapan 2019
Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), today announced… Continue Reading Biosphere tenant Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression.
Atelerix is a spin out from Newcastle University and pioneers in the storage and… Continue Reading Transformational cell technology helping to improve lives across the world
